RxSight Must Litigate Investor Suit Over Eye Lens System Demand

RxSight Inc. must defend against allegations the medical device maker misrepresented the efficacy and patient adoption of its implanted eye lens system designed for use following cataract surgery.

The pension fund leading the case sufficiently alleged the level of intent by CEO Ron Kurtz and former Chief Financial Officer Shelley Thunen to mislead investors, Judge Fred W. Slaughter said, denying a motion from RxSight and the executives to dismiss the proposed class action.

The fund’s complaint alleged “that once RxSight’s poor performance became public, Defendants made statements about utilization and adoption being poorer than they had previously indicated, and admitted ...